Innovent Biologics Inc. Registered Shares o.N.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
2.01%
Market Cap
-
P/E Ratio
144.96
Dividend Yield
0.00 %
Earnings per Share
0.06 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 8.369 G | 0 Units |
| PRICE DETERMINATION TIME | 06/19/2026 / 02:17:09 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 8.375 | 8.233 |
| PREV. DAY'S PRICE | 8.411 | (06/18) |
| CHANGE DAY BEFORE | -0.04 | -0.50 % |
| 52 WEEK HIGH / LOW | 11.5 (09/03) | 7.818 (06/09) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 0.26 | 0.17 | 0.06 | -0.01 | -0.09 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | 32.02 | 50.74 | 144.96 | - | - |
| PRICE - BOOK RATIO | - | - | 6.13 | 4.29 | 5.03 |
| PRICE - SALES RATIO | - | - | 9.39 | 5.83 | 9.72 |
| PRICE - CASH FLOW RATIO | - | - | 11.98 | 30.10 | 184.81 |
Master Data
| WKN | A2N7N8 |
| ISIN | KYG4818G1010 |
| SYMBOL | 6IB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | INNOVENT BIOLOGICS INC. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.93 % | -8.17 % | -10.58 % | -9.59 % | -2.01 % | 94.81 % | -9.09 % | -2.60 % |
| HIGH | 8.49 | 9.29 | 10.10 | 10.10 | 11.50 | 11.50 | 11.50 | 10.10 |
| LOW | 7.83 | 7.82 | 7.82 | 7.82 | 7.82 | 3.26 | 2.22 | 7.82 |
Dividend
per share
INNOVENT BIOLOGICS INC. does not deliver dividend information
Company profile
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.